U.S. FDA approves Pfizer's high profile breast cancer drug

February 3, 2015 9:36 PM

3 0

U.S. FDA approves Pfizer's high profile breast cancer drug

(Reuters) - The U.S. Food and Drug Administration on Tuesday said it had approved Pfizer Inc's experimental breast cancer drug Ibrance, a regulatory decision that came more than two months earlier than expected.

Wall Street has considered the drug, whose chemical name is palbociclib, to be one of the most promising medicines in Pfizer's development pipeline.

Read more

To category page

Loading...